Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EPHB3 | P54753 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991851 | 0.81 | NPC1 (0.42) | NPC1RAB9ADRD4DRD3LMNA | |
| SCHEMBL30645127 | 0.79 | NPC1 (0.38) | NPC1RAB9ADRD4DRD3LMNA | |
| SCHEMBL12875638 | 0.78 | EGFR (0.41) | NPC1RAB9ADRD4DRD3LMNA | |
| SCHEMBL5019489 | 0.76 | MAP4K4 (0.44) | NPC1RAB9ADRD4DRD3LMNA | |
| SCHEMBL22995014 | 0.74 | EPHB3 (0.50) | NPC1RAB9ADRD4DRD3HTT | |
| SCHEMBL19114977 | 0.74 | DRD3 (0.42) | NPC1RAB9ADRD4DRD3DYRK1A | |
| SCHEMBL73454 | 0.74 | AXL (0.47) | NPC1RAB9ADRD4DRD3DYRK1A | |
| SCHEMBL4285576 | 0.74 | CCNK (0.43) | NPC1RAB9ADRD4DRD3DYRK1A | |
| SCHEMBL12456009 | 0.74 | DRD3 (0.42) | NPC1RAB9ADRD4DRD3DYRK1A | |
| SCHEMBL3485186 | 0.74 | DRD3 (0.47) | NPC1RAB9ADRD4DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| WO-2024124002-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123966-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024118488-A1 | 2-PHENYLMORPHOLINE AND 2-PHENYL(THIO)MORPHOLINE COMPOUNDS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024077391-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2024-04-18 | — | — | WO | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2024015251-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20080004270-A1 | 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2008-01-03 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006003440-A1 | 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004270-A1 | 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors | CDK3, CDK1, GSK3B | NPC1 3115/4885RAB9A 3974/4885DRD4 2614/4885 |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | PADI6, PADI4, PADI1 | NPC1 3917/4885RAB9A 3350/4885DRD4 2172/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | NPC1 212/4885RAB9A 1784/4885DRD4 1036/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | NPC1 354/4885RAB9A 2937/4885DRD4 4878/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | NPC1 2920/4885RAB9A 4363/4885DRD4 4413/4885 |
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | NPC1 1220/4885RAB9A 4050/4885DRD4 4875/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | NPC1 536/4885RAB9A 2170/4885DRD4 4855/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | NPC1 4433/4885RAB9A 660/4885DRD4 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.